Tenaya Therapeutics prices $52.5M public offering of units with warrants

Tenaya Therapeutics, Inc.

Priced 75M units at $0.70/unit; gross proceeds ~$52.5M before expenses.
Each unit: one share common + Series A warrant (1 share at $0.80, 5yr) + Series B warrant (0.5 share at $0.70, expires June 30, 2026).
Offering expected to close March 5, 2025; Leerink Partners and Piper Sandler are joint book-runners.
Net proceeds to fund development of TN-201 and TN-401, and for working capital.
Company also terminated ATM prospectus under existing sales agreement with Leerink Partners as of March 3, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.